title: Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT/CT.
abstract: BACKGROUND
  Stereotactic ablative body radiotherapy (SABR) has been proposed as a definitive treatment for patients with inoperable primary renal cell carcinoma. However, there is little documentation detailing the radiobiological effects of hypofractionated radiation on healthy renal tissue.
  
  
  RESULTS
  In this study we describe a methodology for assessment of regional change in renal function in response to single fraction SABR of 26 Gy. In a patient with a solitary kidney, detailed follow-up of kidney function post-treatment was determined through 3-dimensional SPECT/CT imaging and (51)Cr-EDTA measurements. Based on measurements of glomerular filtration rate, renal function declined rapidly by 34% at 3 months, plateaued at 43% loss at 12 months, with minimal further decrease to 49% of baseline by 18 months.
  
  
  CONCLUSIONS
  The pattern of renal functional change in (99m)Tc-DMSA uptake on SPECT/CT imaging correlates with dose delivered. This study demonstrates a dose effect relationship of SABR with loss of kidney function.
authors.affiliation: Department of Physical Sciences, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. Price.Jackson@petermac.org.
authors.forename: Price
authors.initials: P
authors.lastname: Jackson
authors.affiliation: Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. Farshad.Foroudi@petermac.org.|Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia. Farshad.Foroudi@petermac.org.
authors.forename: Farshad
authors.initials: F
authors.lastname: Foroudi
authors.affiliation: Department of Radiotherapy, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. Daniel.Pham@petermac.org.
authors.forename: Daniel
authors.initials: D
authors.lastname: Pham
authors.affiliation: Department of Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. Michael.Hofman@petermac.org.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Hofman
authors.affiliation: Department of Physical Sciences, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. Nicholas.Hardcastle@petermac.org.|Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW, Australia. Nicholas.Hardcastle@petermac.org.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Hardcastle
authors.affiliation: Department of Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. Jason.Callahan@petermac.org.
authors.forename: Jason
authors.initials: J
authors.lastname: Callahan
authors.affiliation: Department of Physical Sciences, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. Tomas.Kron@petermac.org.
authors.forename: Tomas
authors.initials: T
authors.lastname: Kron
authors.affiliation: Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. Shankar.Siva@petermac.org.|Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia. Shankar.Siva@petermac.org.
authors.forename: Shankar
authors.initials: S
authors.lastname: Siva
mesh_terms: D002292:Carcinoma, Renal Cell / Q000601:surgery*; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging* / Q000528:radiation effects*; D007680:Kidney Neoplasms / Q000601:surgery*; D064847:Multimodal Imaging; D011832:Radiation Injuries / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D016634:Radiosurgery / Q000009:adverse effects*; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019783:Technetium Tc 99m Dimercaptosuccinic Acid